โ† All deals

Adze Biotechnology Inc

BiotechnologyBiotechnologyOncolytic ImmunotherapyClinical-Stage
๐Ÿ“ Coral Gables, FL, United Statesโ€ข Founded 2018
StreetZero Signal 76
Be the first to signal interest

About Adze Biotechnology Inc

Adze Biotechnology Inc is a clinical-stage oncolytic immunotherapy platform company with active programs in melanoma, breast cancer, and liver cancer. Its proprietary oncolytic backbone is designed for both systemic and intra-tumoral delivery, allowing variation of IO payloads. The company is headquartered in Coral Gables, Florida, and led by CEO Sidney Hopps.

LATEST FUNDINGPrivate Placement
$9.3M
Announced 2026-11-16
TOTAL RAISED$9.8M
๐Ÿ”’

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Adze Biotechnology Inc.

Free plan includes 3 full deal profiles every month.

Investors

Key highlights

  • Raised $6.2M first close of Series A in March 2023 to advance clinical programs.
  • Platform enables both systemic and intra-tumoral delivery with customizable IO payloads.
  • Actively seeking $30M Series B to fund multiple clinical programs with data readouts in late 2026.
  • Holds Notice of Allowance for broad recombinant adenovirus IP claims.
  • Competitors include Oncorus, Replimune, and Akamis Bio.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account